Genta's Genasense Still a Long Shot
The phase III study enrolled 120 patients who were given a combination of Genasense plus chemotherapy; another 121 patients were given chemotherapy alone. All patients in the study were diagnosed with advanced CLL, which means they had received, and failed, prior therapies.
Nineteen patients, or 16%, in the Genasense arm of the study achieved a major response -- defined as a complete response or so-called nodular partial response, compared to with eight patients, or 7%, in the control arm. This result, the study's primary endpoint, was statistically significant, albeit not robustly so with a so-called p value of 0.039.
But a more conventional primary endpoint in CLL studies looks at overall response rate, defined as a complete response, nodular partial responses and partial response. When the Genasense data were analyzed this way, overall response in the Genasense arm was 41%, less than the 45% overall response rate in the control arm.
Also, patients in the Genasense arm of the study progressed (their disease worsened) at a median time of 6.1 months, faster than the 8.9 months for patients in the control arm. Overall survival data were not analyzed, pending further maturing of the data.Despite a series of setbacks this year that have left Genta reeling, the company seems intent to push ahead with Genasense's development. No doubt, persistence sometimes pays off. But for Genta, the second time will not likely be the charm.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV